ConductScience.org, home

Paper39641

Is there a limbic system equivalent of tardive dyskinesia?

Davis KL and 1 other. Biol Psychiatry, 1979. Cited by 55 papers, by iCite.

Cite this record

ConductScience Library. Is there a limbic system equivalent of tardive dyskinesia? Papers, record 39641. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39641

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Is there a limbic system equivalent of tardive dyskinesia?
PubMed
Journal
Biol Psychiatry
PubMed
Year
1979
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
55
iCite
Relative citation ratio, by iCite
2.43
iCite
Revised in PubMed
2013-11-21
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Davis KLK L
2Rosenberg GSG S

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Dyskinesia, Drug-InducedMajor topic
Limbic SystemMajor topic
Animals
Antipsychotic Agents
Dose-Response Relationship, Drug
Fluphenazine
Humans
Mesencephalon
Neural Pathways
Receptors, Dopamine
Schizophrenia

Source PubMed

Download CSV of topics

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 55 citations.

PMIDTitleJournalYearIn PapersSource
42397413Dopamine supersensitivity psychosis: a critical evaluation of diagnostic validators.J Neural Transm (Vienna)2026https://conductscience.org/library/papers/42397413PubMed
36760795Enhancement of adenosine A2A signaling improves dopamine D2 receptor antagonist-induced dyskinesia via β-arrestin signaling.Front Neurosci2022https://conductscience.org/library/papers/36760795PubMed
23821039Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.CNS Drugs2013https://conductscience.org/library/papers/23821039PubMed
22249643Adolescent female with withdrawal psychosis following abrupt termination of ziprasidone.Eur Child Adolesc Psychiatry2012https://conductscience.org/library/papers/22249643PubMed
21402722Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis.Schizophr Bull2012https://conductscience.org/library/papers/21402722PubMed
8935814Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine.Psychopharmacology (Berl)1996https://conductscience.org/library/papers/8935814PubMed
6784143Increased mesolimbic dopamine binding following chronic haloperidol treatment.Psychopharmacology (Berl)1981https://conductscience.org/library/papers/6784143PubMed
2292234Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.Drugs1990https://conductscience.org/library/papers/2292234PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39641

GET https://conductscience.org/api/papers/v1/39641/authors